Market Movers: Cyclacel (CYCC) Jumps 6.90% to Close at $1.24 August 4

Equities Staff  |

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) stock was among today's market movers, finishing trading up 6.90% to $1.24 on August 4.

1,030,982 shares traded hands while the 30-day daily average of 1,210,418 shares.

The company's stock has risen 70.18% so far in 2022.

Cyclacel shares have fluctuated between $1.01 and $6.10 over the past twelve months.

The company is set to release earnings on 2022-08-10.

For technical charts, analysis, and more on Cyclacel visit the company profile.

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced solid cancers and in combination with venetoclax in patients with advanced hematological malignancies, including CLL and AML. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive patients with advanced solid cancers and a concomitant regimen of sapacitabine and olaparib, a PARP inhibitor, in BRCA positive patients with breast cancer. CYC140, a PLK inhibitor, is in a Phase 1 first-in-human study in patients with advanced leukemias. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.

To get more information on Cyclacel Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Cyclacel Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

testforhref
The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content